{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"jRCT2051260010","nct_id":"NCT06427941","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=jrct2051260010-nct06427941. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive ascending dose levels of BGB-B2033 monotherapy","label":"Part A (Monotherapy Dose Escalation and Safety Expansion)","type":"EXPERIMENTAL"},{"description":"Participants will receive BGB-B2033 in combination with tislelizumab and to inform the starting dose of BGB-B2033 for subsequent triplet dose escalation.","label":"Part B (Doublet Run-in)","type":"EXPERIMENTAL"},{"description":"Participants will receive BGB-B2033 in combination with tislelizumab and bevacizumab to determine the maximum tolerated dose (MTD), maximum administered dose (MAD), and recommended dose for expansion (RDFE) of the combination.","label":"Part B (Triplet Dose Escalation)","type":"EXPERIMENTAL"},{"description":"Safety expansion arm for each combination therapy cohort (triplet and doublet)","label":"Part B (Triplet and Doublet Safety Expansion)","type":"EXPERIMENTAL"},{"description":"Participants in Asian countries with HCC will receive BGB-B2033 as monotherapy.","label":"Part C (Asia Monotherapy Dose Expansion in HCC)","type":"EXPERIMENTAL"},{"description":"Participants in the United States (US) with HCC will receive BGB-B2033 as monotherapy.","label":"Part D (US Monotherapy Dose Expansion in HCC)","type":"EXPERIMENTAL"},{"description":"Participants with HCC will receive BGB-B2033 as monotherapy.","label":"Part E (Monotherapy Dose Expansion in HCC)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"conditions":["Metastatic Hepatocellular Carcinoma","Local Advanced Hepatocellular Carcinoma","Alpha-fetoprotein (AFP)-Producing Gastric Cancer","Extragonadal Yolk Sac Tumors","Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer"],"enrollment":{"count":630,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BGB-B2033","otherNames":[],"type":"DRUG"},{"name":"Tislelizumab","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-16","lead_sponsor":"BeOne Medicines","official_title":"A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to approximately 2 years"},{"measure":"Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033","timeFrame":"Up to approximately 2 years"},{"measure":"Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033","timeFrame":"Up to approximately 2 years"},{"measure":"Parts C, D, and E: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2024-07-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06427941"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/jrct2051260010-nct06427941"}